Ipsen is a global specialty driven pharmaceutical company with total sales exceeding . billion in . Ipsen s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology, endocrinology and uro oncology. Moreover, the Group has an active policy of partnerships. R amp D is focused on innovative and differentiated technological patientdriven platforms, peptides and toxins. In , R amp D expenditure totaled close to million, representing more than of Group sales. The Group has total worldwide staff of close to , employees.
Quote | Ipsen Sa Ord (OTCMKTS:IPSEF)
Last: | $117.60 |
---|---|
Change Percent: | 0.0% |
Open: | $0 |
Close: | $117.60 |
High: | $0 |
Low: | $0 |
Volume: | 62 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Ipsen Sa Ord (OTCMKTS:IPSEF)
2024-04-24 02:26:32 ET More on Ipsen S.A. Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors Ipsen, Skyhawk enter RNA targeting research collab in rare neurological diseases Ipsen secures exclusive global rights of Sutro Biopharma's STR...
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. Highlights Total-sales growth of 13.3% at CER 1 , or 10.9% as reported, driven by the 16.2% ...
Message Board Posts | Ipsen Sa Ord (OTCMKTS:IPSEF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Ipsen Sa Ord Company Name:
IPSEF Stock Symbol:
OTCMKTS Market:
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. Highlights Total-sales growth of 13.3% at CER 1 , or 10.9% as reported, driven by the 16.2% ...
Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise...
Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical development STRO-003 targets ROR1, a clinically validated antibody drug conjugate (ADC) target STRO-003 has shown robust...